Wil Helmus schreef op 9 oktober 2019 14:07:
Ik heb geen idee. Zie nog wel dit voorbij komen:
ProQR shares could more than double on tomorrow's data, says Cantor FitzgeraldCantor Fitzgerald analyst Eliana Merle reiterates an Overweight rating on ProQR Therapeutics with a $40 price target ahead of tomorrow's data update on lead program QR-110, which is in development for LCA10, a rare genetic form of blindness. Investors view ProQR and QR-110 as a "show-me story," but these data could lift a "significant overhang" around platform safety and serve as a "key piece of clinical de-risking" for QR-110's Phase 2/3 trial under way, Merle tells investors in a research note partially titled "A double by this time tomorrow?". The analyst thinks the stock could trade up 50%-150% tomorrow versus downside to its cash position of ~$2 per share, or ~65%.
Read more at:
thefly.com/landingPageNews.php?id=297...